Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Prostatic Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1NSCLC 1Mucopolysaccharidosis I 1Metastatic Castration-resistant Prostate Cancer 1Liposarcoma 1Hodgkin Disease 1Disease Progression 1Carcinoma in Situ 1

Interventions

Trabectedin 4Doxorubicin 4toripalimab 2brigimadlin 2belinostat 2Fulvestrant 2Dexamethasone 2tanespimycin 1soblidotin 1siremadlin 1selinexor 1ridaforolimus 1ribociclib 1pembrolizumab 1olaratumab 1milademetan 1enzalutamide 1cemiplimab 1atezolizumab 1TTI-621 1Sugars 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Midazolam 1Letrozole 1Injections 1Immunotherapy 1Imatinib Mesylate 1Ifosfamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Liposarcoma × Clinical Trials, Phase I as Topic × Clear all
NCT06578624 2025-06-05

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

Lamassu Bio Inc

Phase 1/2 Recruiting
70 enrolled
Sarcoma

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡